396
Participants
Start Date
October 28, 2019
Primary Completion Date
August 23, 2022
Study Completion Date
August 22, 2023
CT-P13 SC (Infliximab)
Subcutaneous injection of CT-P13 SC
Placebo SC
Subcutaneous injection of Placebo SC
Biopharma Informatic - Houston, Houston
Vitebsk Regional Clinical Hospital, Vitebsk
Diagnostic and Consulting Center Aleksandrovska EOOD, Sofia
Clinical Hospital Centre Osijek, Osijek
Fakultni nemocnice Ostrava, Ostrava
Centre Hospitalier Lyon Sud, Pierre-Bénite
Praxis Prof. Herbert Kellner, München
University General Hospital of Heraklion, Heraklion
Debreceni Egyetem Klinikai Kozpont, Debrecen
Nirmal Hospital, Surat
Sheba Medical Center, Ramat Gan
Fondazione Policlinico Universitario A Gemelli-Rome, Roma
Tsujinaka Hospital, Kashiwa
Pauls Stradins Clinical University Hospital, Riga
BRCR Global Mexico, Guadalajara
IMSP Institute of Clinical Cardiology, Chisinau
Hospital Nacional Cayetano Heredia, San Martín de Porres
Szpital Uniwersytecki Nr 2 im. dr Jana Biziela w Bydgoszczy, Centrum Endoskopii Zabiegowej, Poradnia, Bydgoszcz
WIP Warsaw IBD Point Profesor Kierkus, Warsaw
Dr.Carol Davila Emergency University Central Military Hospital, Bucharest
Klinika YZI 4D, Pyatigorsk
BioTekhServis, Saint Petersburg
Clinical Hospital Centar Zvezdara, Belgrade
Fakultna nemocnica s poliklinikou F. D. Roosevelta, Banská Bystrica
CLINRESCO, ARWYP Medical Suites, Johannesburg
Hospital Arquitecto Marcide, Ferrol
Ege University Medical Faculty, Izmir
Communal Non-Commercial Enterprise Cherkasy Regional Hospital of Cherkasy Regional Council, Cherkassy
Municipal Nonprofit Enterprise Zaporizhzhia Regional Clinical Hospital Zaporizhzhia Regional Council, Zaporizhzhia
Lead Sponsor
Celltrion
INDUSTRY